SPA
FOLD

Sherbrooke Park Advisers’s Amicus Therapeutics FOLD Stock Holding History

Sherbrooke Park Advisers’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-29,539
Closed -$169K – 588
2025
Q2 		$169K Buy
29,539
+14,266
+93% +$92.1K 0.07% 416
2025
Q1 		$125K Sell
15,273
-6,263
-29% -$58K 0.06% 488
2024
Q4 		$203K Sell
21,536
-6,893
-24% -$71.6K 0.06% 585
2024
Q3 		$304K Buy
+28,429
New +$310K 0.07% 559
2024
Q2 		– Sell
-46,802
Closed -$551K – 1010
2024
Q1 		$551K Buy
+46,802
New +$599K 0.11% 326

Other funds holding FOLD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Sherbrooke Park Advisers's FOLD Position: Q3 2025 in Review

Sherbrooke Park Advisers sold out of Amicus Therapeutics (FOLD) in Q3 2025, closing a stake of 29,539 shares — an estimated $169K sold.

Sherbrooke Park Advisers first reported a position in FOLD in Q1 2024 and held it in 5 quarters. The position peaked at $551K in Q1 2024. 287 funds tracked by Wall St. Rank hold FOLD as of Q3 2025.

  • Sherbrooke Park Advisers reported no remaining Amicus Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Sherbrooke Park Advisers sold 29,539 Amicus Therapeutics shares in Q3 2025, an estimated $169K.
  • Sherbrooke Park Advisers first reported a position in Amicus Therapeutics in Q1 2024 and held it in 5 quarters.
  • Sherbrooke Park Advisers's Amicus Therapeutics position peaked at $551K in Q1 2024.
  • 287 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q3 2025.

Based on Sherbrooke Park Advisers's 13F filing for Q3 2025, filed 14 Nov 2025.